Showing 4801-4810 of 19421 results for "".
Effective Acute Pain Management Strategies for Adult Patients
https://reachmd.com/programs/clinicians-roundtable/effective-acute-pain-management-strategies-for-adult-patients/26726/Tune in to hear expert insights on the current approaches to treating acute pain in adults.A Practical Guide to Chronic Spontaneous Urticaria
https://reachmd.com/programs/on-the-frontlines-of-chronic-spontaneous-urticaria/a-practical-guide-to-chronic-spontaneous-urticaria/56726/Chronic spontaneous urticaria is a complex and often frustrating condition characterized by recurrent hives and itching without an identifiable trigger, often taking a significant toll on patients’ daily lives. Gaining a better understanding of its underlying biology can help clinicians make more coProtecting Heart Health in Metastatic Breast Cancer
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/protecting-heart-health-in-metastatic-breast-cancer/39717/Metastatic breast cancer treatments have extended survival, but many therapies carry important cardiovascular risks that can impact long-term quality of life. As patients live longer, understanding the cardiac effects of these therapies is increasingly critical. Joining Ryan Quigley to discuss riskDecoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
https://reachmd.com/programs/neurofrontiers/decoding-disability-worsening-in-ms-the-case-for-combining-csf-and-serum-biomarkers/32824/A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward moreClinical Data on Switching to Upadacitinib
https://reachmd.com/series/updates-atopic-dermatitis/clinical-data-on-switching-to-upadacitinib/36534/Clinical investigator Christopher Bunick, MD, PhD, discusses results from the LEVEL UP trial among patients who switched from dupilumab to upadacitinib for atopic dermatitis.Advocacy and Research
https://reachmd.com/series/the-practical-dermatology-podcast/advocacy-and-research/36479/The latest news and updates, plus Harrison Nguyen, MD, MBA, MPH, FAAD, discusses addressing barriers to maximizing biologics for psoriasis, and Mark Lebwohl, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about some of the latest research he has been involvOptimizing Surgical Wound Outcomes: A Focus on Evidence-Based Care
https://reachmd.com/programs/clinicians-roundtable/optimizing-surgical-wound-outcomes-a-focus-on-evidence-based-care/35841/Successful surgical wound care goes beyond closure—it’s also about minimizing complications, reducing readmissions, and aligning with patient-reported outcomes like pain control and daily activity readiness. Hear from Ms. Kara Couch as she explores how standardization, documentation, and evidence-baDebunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
https://reachmd.com/programs/project-oncology/debunking-car-t-cell-myths-the-realities-of-patient-selection-safety-and-access/35452/This is a non-certified educational series produced and controlled by ReachMD. Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record stTransforming C3G Care: New Advances in Targeted Treatment
https://reachmd.com/programs/frontlines-c3g/transforming-c3g-care-new-advances-in-targeted-treatment/35488/With the recent approval of iptacopan and promising data on pegcetacoplan emerging, targeted therapy is becoming a reality for patients with complement 3 glomerulopathy (C3G). Hear from Dr. Gates Colbert and Dr. Anuja Java as they dive into the details of newer treatments, key considerations for patRedefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
https://reachmd.com/programs/frontlines-prostate-cancer/redefining-mhspc-treatment-from-monotherapy-to-triplet-therapy-regimens/32220/Androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPi) is increasingly considered the standard of care for most patients with metastatic hormone-sensitive prostate cancer (mHSPC), but ADT monotherapy is still reserved for well-justified exceptions. And moving forward,